EGFR and lung carcinoma: We also examined DPP4 expression in tumor tissues from lung cancer patients by immunohistochemistry, and found that DPP4 was significantly upregulated in the residual tumor tissues after osimertinib treatment compared to the tumor tissues from patients who did not receive EGFR‐TKIs (Figure 1F–G).